In HF, T2D, CKD, or atherosclerotic CVD, SGLT2 inhibitors reduce HF hospitalizations and CV mortality. Zhu D, Herrington WG. Ann Intern Med 2024;177:JC123.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zhu D, Herrington WG. In HF, T2D, CKD, or atherosclerotic CVD, SGLT2 inhibitors reduce HF hospitalizations and CV mortality. Ann Intern Med 2024;177:JC123.
PMID: 39496169